Invention Grant
- Patent Title: Immunomodulatory fusion proteins
-
Application No.: US17150993Application Date: 2021-01-15
-
Publication No.: US12054530B2Publication Date: 2024-08-06
- Inventor: Christopher Larson , Tony R. Reid , Bryan T. Oronsky
- Applicant: EpicentRx, Inc.
- Applicant Address: US CA La Jolla
- Assignee: EpicentRx, Inc.
- Current Assignee: EpicentRx, Inc.
- Current Assignee Address: US CA La Jolla
- Agency: Morrison & Foerster LLP
- Main IPC: C07K14/71
- IPC: C07K14/71 ; A61K35/768 ; A61K38/00 ; A61K48/00 ; A61P35/00 ; C07K16/00 ; C12N7/00 ; C12N15/86

Abstract:
Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., a TGFβ trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion proteins, or expression vectors encoding for the fusion proteins, e.g., oncolytic adenoviral expression vectors, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.
Public/Granted literature
- US20210139560A1 IMMUNOMODULATORY FUSION PROTEINS Public/Granted day:2021-05-13
Information query